Cargando…
Advantages of the AMDL-ELISA DR-70 (FDP) Assay over Carcinoembryonic Antigen (CEA) for Monitoring Colorectal Cancer Patients
The DR-70® (FDP) test was the first cancer test cleared by USFDA for monitoring colorectal cancer (CRC) since Carcinoembryonic Antigen (CEA) in 1982. Conservatively, 50% of biopsy-positive CRC patients have negative CEA values. DR-70 and CEA values were compared for 113 CRC monitoring patients. Tota...
Autores principales: | Small-Howard, Andrea L., Harris, Holden |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2872273/ https://www.ncbi.nlm.nih.gov/pubmed/20391025 http://dx.doi.org/10.1080/15321811003617438 |
Ejemplares similares
-
Carcinoembryonic antigen (CEA) "fingerprints".
por: Rule, A. H., et al.
Publicado: (1973) -
A monkey antigen crossreacting with carcinoembryonic antigen, CEA.
por: Engvall, E., et al.
Publicado: (1976) -
First British standard for carcinoembryonic antigen (CEA).
por: Laurence, D. J., et al.
Publicado: (1975) -
Immunochemical studies of carcinoembryonic antigen (CEA) variants.
por: Ichiki, A. T., et al.
Publicado: (1976) -
Epitopes of carcinoembryonic antigen (CEA) defined by monoclonal antibodies.
por: Price, M. R.
Publicado: (1988)